HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).

Abstract
In a phase II study including 80 patients treated with highly emetic drugs such as cisplatin, carboplatin or cyclophosphamide > 600 mg/day) we confirmed the potential of ondansetron to prevent cancer chemotherapy- related acute nausea and vomiting. With a total dose of 19.0-37.3 mg ondansetron we achieved 82%-100% acute (0-24 hours) vomiting free patients. Using ondansetron for the prevention of acute nausea and vomiting increases the total chemotherapy costs by 6%. The real cost-benefit ratio for the treatment of acute nausea and vomiting shows better values for ondansetron than for all other recommended regimens.
AuthorsS Tanneberger, G Lelli, A Martoni, E Piana, F Pannuti
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 4 Issue 5 Pg. 326-31 (Oct 1992) ISSN: 1120-009X [Print] England
PMID1479424 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Ondansetron
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (adverse effects)
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nausea (chemically induced, drug therapy)
  • Ondansetron (economics, therapeutic use)
  • Technology Assessment, Biomedical (methods)
  • Vomiting (chemically induced, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: